Department of Ophthalmology, First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
Ophthalmologica. 2009;223(6):401-10. doi: 10.1159/000228926. Epub 2009 Jul 20.
As researchers and clinicians are beginning to understand that wet age-related macular degeneration (AMD) is more than simply a vascular disease that includes angiogenic, vascular and inflammatory components, they are exploring new agents with different mechanisms of action addressing multiple targets in this complex pathophysiology. Some of them are already available in human trials or even approved vascular epithelial growth factor (VEGF) blockers such as Macugen, Lucentis, Avastin, VEGF Trap-Eye and Cand5; VEGF receptor blockers such as TG100801, vatalanib, pazopanib, Sirna-027 and a vaccine approach; inflammation inhibitors and immunosuppressants such as Retaane, Kenalog, ARC1905, POT-4, OT-551. The last group is mixed, containing agents such as Zybrestat, AdPEGF, Sirolimus, JSM6427, ATG003, E10030. This article reviews these currently emerging agents and briefly discusses the next step for the treatment of wet AMD.
随着研究人员和临床医生开始认识到湿性年龄相关性黄斑变性（AMD）不仅仅是一种血管疾病，其中包括血管生成、血管和炎症成分，他们正在探索具有不同作用机制的新药物，以针对这种复杂的病理生理学中的多个靶点。其中一些药物已经在人体试验中可用，甚至已经批准了血管内皮生长因子（VEGF）抑制剂，如 Macugen、Lucentis、Avastin、VEGF Trap-Eye 和 Cand5；VEGF 受体抑制剂，如 TG100801、vatalanib、pazopanib、Sirna-027 和疫苗方法；炎症抑制剂和免疫抑制剂，如 Retaane、Kenalog、ARC1905、POT-4、OT-551。最后一组是混合的，包含 Zybrestat、AdPEGF、西罗莫司、JSM6427、ATG003、E10030 等药物。本文综述了这些目前新兴的药物，并简要讨论了湿性 AMD 治疗的下一步措施。
